Next Article in Journal
Difficult-to-Engage Patients with Severe Mental Illness in Rural Community Settings: Results of the Greek Hybrid Assertive Community Treatment Model of Mental Healthcare
Previous Article in Journal
Long-Term Improvement of Different Types of Acne Vulgaris Using a Mild Photodynamic Therapy Protocol with BF-200 ALA Gel: A Series of Cases
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Risk Factors for Lymph Node Metastasis in a Western Series of Patients with Distal Early Gastric Cancer

1
Unità Operativa di Chirurgia Generale, Dipartimento di Chirurgia, Azienda Sanitaria Provinciale, 87100 Cosenza, Italy
2
Unità Operativa di Chirurgia Generale e Oncologica, Azienda Ospedaliera di Rilevanza Nazionale San Giuseppe Moscati, 83100 Avellino, Italy
3
Unità Operativa di Chirurgia d’Urgenza e del Trauma, Dipartimento Scienze Mediche e Chirurgiche Addominali ed Endocrino Metaboliche, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Fondazione Policlinico Universitario Agostino Gemelli, 00168 Roma, Italy
4
Unità Operativa di Chirurgia Oncologica Della Tiroide e Della Paratiroide, Istituto Nazionale Tumori, IRCCS Fondazione Pascale, 80100 Napoli, Italy
5
Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Roma, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2024, 13(9), 2659; https://doi.org/10.3390/jcm13092659
Submission received: 27 March 2024 / Revised: 22 April 2024 / Accepted: 29 April 2024 / Published: 1 May 2024
(This article belongs to the Section Oncology)

Abstract

:
Background: Assessment of potential lymph node metastasis is mandatory in the appropriate treatment of early gastric cancers. This study analysed factors associated with lymph node metastasis to identify differences between node-negative and node-positive patients and between T1a and T1b cancers. Methods: The clinicopathological features of 129 early gastric cancer patients who had undergone radical gastrectomy were analysed to identify predictive factors for lymph node metastasis. Results: Lymph node metastasis was detected in 76 (59.0%) patients. Node-positive patients were younger (58.1 ± 11.3 years) than those without metastasis (61.9 ± 9.6 years, p = 0.02). Greater tumour sizes were observed in patients with lymph node metastasis (3.6 ± 1.0 cm) compared to node-negative patients (1.9 ± 0.5 cm, p = 0.00001). Depressed form, ulceration, diffuse histological type, and undifferentiated lesions were more frequent in node-positive patients than in the node-negative group. Tumour size > 3.0 cm showed a correlation with lymph node metastasis in both T1a (p = 0.0001) and T1b (p = 0.006) cancer. The male sex (p = 0.006) had a significant correlation with lymph node metastasis in T1a cancer. Depressed appearance (p = 0.02), ulceration (p = 0.03), differentiation (p = 0.0001), diffuse type (p = 0.0002), and lower third location (p = 0.005) were associated with lymph node metastasis in T1b cancer. Conclusions: Tumour size > 3 cm, undifferentiated lesions, ulceration, diffuse type, lower third location, and submucosal invasion are risk factors for lymph node metastasis in early gastric cancer.

1. Introduction

Gastric cancer is a malignancy with great heterogenicity [1]. The application of the same standard to all patients in different conditions may lead to treatment bias [1,2,3,4]. In early gastric cancer (EGC), the depth of invasion is limited to the mucosa (T1a) and submucosa (T1b), regardless of lymph node (LN) involvement [3,5,6]. The lymphatic system plays an important role in the spread of gastric cancer and intramucosal growth is sufficient to cause lymph node metastasis (LNM) [7,8,9]. Although gastrectomy has been associated with superior survival compared with alternative procedures, endoscopic resection and limited surgery have been widely accepted as a curative therapy for small T1 cancers [10,11] in order to reduce perioperative complications and improve quality of life. In this scenario, a preoperative assessment of risk factors for LNM based on clinicopathological factors may be useful for optimal treatment planning [3,9,12]. It is a significant prognostic factor for EGC, because the disease is believed to be curable [2,13,14]. Although there has been substantial research on the prediction of risk factors for LNMs in EGC, no definitive criteria are available [15]. Risk factors for LNM are well established in Eastern countries [5,16,17]. Nevertheless, an analysis of predictive factors for LNMs in EGC remains uncommon in the West, where series of patients are smaller in comparison to the East [3,17,18,19,20]. Moreover, the risk of LNMs in Western patients with EGC is higher, probably due to a higher incidence of T1b cancers [21,22]. In these patients, radical surgery with formal LN dissection has become the standard treatment [3,23,24,25]. Therefore, it was noted that about 70–80% of patients undergo unnecessary extended LN dissection. The present study was designed to evaluate the factors that can predict the presence of LNMs. The primary aim of this study is to evaluate the factors determining the prevalence of LNMs. An evaluation of factors is performed to identify the difference between T1a and T1b cancers and between node-negative and LNM patients.

2. Materials and Methods

A retrospective analysis was conducted on EGC patients who had undergone D2 radical gastrectomy at Fondazione Policlinico Universitario “A Gemelli” IRCCS and at the Department of Surgery, Azienda Sanitaria Provinciale Crotone, over a 15-year period. This study followed the STROBE reporting guidelines [26]. This study was conducted in accordance with the Declaration of Helsinki. All patients provided written consent before the surgical procedures.
Patients were eligible if they met the following inclusion criteria: 1. middle third or lower third EGC; 2. lymphadenectomy with more than 16 LNs harvested. Patients with advanced gastric cancer or neoplasms other than gastric adenocarcinoma, EGC occurring in the esophagogastric junction, in the upper third, and EGC of the gastric stump, those undergoing endoscopic resection or neoadjuvant treatment, or those with missing histopathological data were excluded.
EGC was divided into T1a and T1b according to the depth of invasion, as indicated in the AJCC Cancer Staging system [27]. The location of the tumour was defined according to the JGCA classification. The maximum diameter of the tumour was recorded as tumour size. Macroscopic type included elevated and depressed. Histopathological classification followed the Lauren criteria [28]. The intestinal and mixed type were grouped as intestinal tumours. Tumour histology was classified into a differentiated type, which included papillary adenocarcinoma and well- or moderately differentiated adenocarcinoma, and an undifferentiated type, which included poorly or undifferentiated adenocarcinoma, signet ring cell carcinoma, and mucinous carcinoma. Lesions with ulceration or scarring from previous ulceration were regarded as ulcerated lesions.
Total or subtotal gastrectomy always included omentectomy and cholecystectomy. Cholecystectomy was performed both in patients with documented gallstones and in patients without concomitant biliary disease. This was because in all patients, for reconstruction, the Roux-en-Y technique was performed. The JGCA guidelines were used for the definition of D2 lymphadenectomy [29]. N stage was classified into four levels based on the number of LNMs, as follows: N0, no regional LMN; N1, 1 to 2 LNMs; N2, 3 to 6 LNMs; N3, >7 LNMs. Each LN station was removed, classified, and then submitted to histopathological examination, as specified elsewhere [6,30].
The evaluated parameters included patient age, sex, tumour size, tumour site at endoscopy, Lauren’s histological type, tumour differentiation, presence of ulceration, macroscopic appearance, depth, N stage, and number of retrieved LNs and LNMs. Subgroups were identified in relation to age (≤65 years and >65years), tumour size (≤3.0 cm and >3.0 cm), longitudinal localisation (GRE—tumours of the greater curvature and LESS—tumours of the lesser curve), and circular localisation (M—tumours in the distal two-thirds of the gastric corpus and L—tumours in antrum or pylorus).
The primary endpoint of this study was to evaluate the factors determining the prevalence of LNMs. The evaluation of factors was performed to identify the differences between T1a and T1b cancers and between node-negative and LNM patients.
Data are expressed as means ±standard deviations (±SD) or as percentages. Data were analysed using GraphPad Prism Software (GraphPad, San Diego, CA, USA). A comparison of means ±SD was performed with the two-tailed t-test. A univariate analysis was performed on all potential factors using the two-tailed chi-square test or Fisher’s exact test for categorical data and the ANOVA test for continuous data in groups larger than two. Multivariate logistic regression was performed by constructing models that took into consideration potential factors with a p value < 0.25 in the univariate analysis, according to the Hosmer–Lemeshow rule. A p value < 0.05 was considered statistically significant.

3. Results

This study involved 129 patients. Their demographic and clinicopathological characteristics are reported in Table 1.
The median age of the enrolled patients was 59.7 ± 10.8 years (range = 35–78 years).
The average size of the tumour was 2.9 ± 1.2 cm (range = 1.0–7.5 cm). Larger tumour sizes, depressed forms, ulceration, diffuse types, undifferentiated lesions, and GRE tumours, were seen in younger and male patients.
Greater tumour sizes were observed in T1b EGC and in LNM patients, rather than in T1a cancer and in node-negative patients (Table 2).
All patients received subtotal or total gastrectomy with D2 LN dissection depending on tumour location. Gallstones were documented in 11 (8.5%) patients.
LN dissection of the splenic hilum involved splenectomy in 32 (24.8%) cases. In all patients, the mean total nodal yield was 40.4 ± 5.3 (range = 31–62).
LNM was detected in 76 (59.0%) patients. Among T1 patients, 35 (44.3%) had LNMs, while in T1b patients, the incidence of LNMs was 82.0% (p = 0.0001).
Table 3 shows the number of LNMs in relation to clinicopathologic variables in node-positive patients. The female sex is directly related to the number of LNMs.
Higher numbers of LNMs were documented in tumours > 3 cm, in depressed aspect, presence of ulceration, diffuse type, undifferentiated tumours, and L location. Higher numbers of LNMs were documented in T1b cancer and in patients undergoing subtotal gastrectomy.

3.1. Risk Factors in T1a and T1b Patients

Table 4 shows the clinicopathologic characteristics of these two groups of patients.
There was no significant difference between T1a and T1b patients in terms of age (59.8 ± 11.4 years vs. 59.3 ± 9.7 years, p = 0.4) and retrieved LNs (40.0 ± 5.3 vs. 40.8 ± 5.3, p = 0.3). Patients with T1b cancer had larger tumour sizes (3.5 ± 1.3 cm vs. 2.5 ± 0.9 cm, p = 0.0001) and more LNMs (2.4 ± 1.0 vs. 1.3 ± 0.5, p = 0.00001) than patients with T1a cancer. The diffuse histologic type was observed significantly more often in mucosal cancer (73.4%) than in submucosal cancer (32.0%). Undifferentiated forms (64.0% vs. 26.5%), depressed-type macroscopic appearance (58.0% vs. 16.4%), and ulceration (54.0% vs. 15.1%) were observed significantly more often in T1b cancer than in T1a cancer. All LNMs in T1a cancer were found to be N1.
There were no significant differences regarding age between patients with LNMs and those without LNMs, both in T1a cancer (57.6 ± 13.2 years vs. 61.6 ± 9.6 years, p = 0.1) and in the T1b group (58.4 ± 9.6 years vs. 63.7 ± 9.7 years, p = 0.1). Greater tumour sizes were observed in LNM patients, both in T1a cancer (3.3 ± 0.7 cm vs. 1.8 ± 0.5 cm, p = 0.00001) and in T1b cancer (3.8 ± 1.2 cm vs. 2.1 ± 0.8 cm, p = 0.0001).
There were no differences in the number of retrieved LNs between patients with and without LNMs in both T1a (N0 40.8 ± 6.2 vs. LNM 39.0 ± 3.7, p = 0.1) and T1b cancer (N0 39.9 ± 2.0 vs. LNM 41.1 ± 5.8, p = 0.2).
Univariate analysis indicated that the male sex, tumour size > 3.0 cm, depressed-type appearance, ulceration, undifferentiated type, and diffuse Lauren’s criteria were risk factors for LNM in T1a EGC. In T1b patients, univariate analysis showed that L location had an association with LNMs. In these patients, tumour size > 3.0 cm, depressed lesion, ulceration finding, and the diffuse type were more frequent in the LMN group (Table 5).

3.2. Risk Factors for LNMs

There were no significant differences between patients with and without LNMs in terms of circular and longitudinal tumour location and the number of retrieved LNs (40.7 ± 5.7 in node-negative patients vs. 40.1 ± 5.0 in LNM patients, p = 0.5).
Patients with LNMs were younger than those without LNMs (58.1 ± 11.3 vs. 61.9 ± 9.6, p = 0.02). Depressed form, ulceration, diffuse histological type, and undifferentiated lesions were more frequent in LNM patients than in the node-negative group (Table 6).
In node-negative patients (53 cases), there were no significant differences between the T1a and T1b groups regarding age (T1a 61.6 ± 9.6 years vs. T1b 63.7 ± 9.7 years, p = 0.2), size of the tumour (T1a 1.9 ± 0.5 cm vs. T1b 2.1 ± 0.8 cm, p = 0.2), and retrieved LNs (T1a 40.8 ± 6.2 vs. T1b 39.9 ± 2.0, p = 0.3). In these patients, there were no significant differences between the T1a and T1b groups for the considered variables (Table 7).
In the LNM group, there were no significant differences between T1a and T1b patients in terms of age (57.6 ± 13.2 years vs. 58.4 ± 9.6, p = 0.3), size of the tumour (3.3 ± 0.7 cm vs. 3.8 ± 1.5 cm, p = 0.05), and LNs retrieved (39.0 ± 3.6 vs. 41.0 ± 5.8, p = 0.07). In these patients, the female sex (p = 0.01), depressed form (p = 0.0006), ulceration (p = 0.002), diffuse type (p = 0.0004), and undifferentiated lesions (p = 0.001) were more frequent in the T1b than in the T1a group.
Multivariate analysis revealed that tumour size greater than 3.0 cm, submucosal invasion, poor tumour differentiation, ulceration, and the diffuse type were risk factors associated with LNMs. Also, lower third location was a risk factor for LNMs (Table 8).

4. Discussion

EGC has a generally excellent prognosis, with the 5-year survival rate exceeding 90% after curative resection [2,3,5,10,16,19,29,31,32,33,34,35,36]. This scenario can be changed by LNMs, because node-positive patients show a significant decline in survival expectancy [3,16]. LNM is a critical factor for determination of therapeutic modalities [3,9,15].
In the past 20 years, D2 lymphadenectomy was considered to be the most appropriate therapy for EGC not amenable to less invasive treatment to achieve curative resection, where the LNM rate ranges from 10% to 42% [3,10,23]. This means that multiple patients underwent unnecessary LN dissection. Consequently, the clinicopathological risk factors for LNM are the key to the surgery rationale in EGC.
The present study found a relatively high LNM incidence in patients with EGC, which was notably higher than that of the Japanese cohort. Despite the different rates of LNM, analyses of risk factors for LNM revealed a similar finding with those reported in the literature. It was found that there were no significant differences in age or gender in EGC with or without LNM. However, a more aggressive biological behaviour and a higher risk of LNM were more frequently showed in younger patients [37]. In fact, larger tumour sizes and higher numbers of LNMs were seen in younger patients in this study. It was also indicated that the female sex was an independent risk factor for LNM in EGC patients [24]. In female patients, the biological behaviour of gastric cancer might be more aggressive, and this may not be fully dependent on tumour size. We noted that tumour sizes were greater in male rather than in female patients (p = 0.02), while higher numbers of LNMs were found in female patients than in male patients (p = 0.04). A possible explanation for the fact that gastric cancer tends to be more invasive in females could be related to endogenous oestrogen levels, which might promote tumour growth.
It has been suggested that ulcerative findings, a depressed appearance, diffuse type, and undifferentiated lesions are risk factors for LNM in EGC [5,8,13,17,22]. Depressed types tend to have higher rates of LNM in T1b cancer. The level of differentiation was an independent factor for LNM in EGC, with the rate of LNM in the undifferentiated type higher (from 13.6% to 32.5%) than the undifferentiated type (from 6.5% to 17.0%). Furthermore, it has been found that the LNM rate is 0.9% in the intestinal type and 4.2% in the diffuse type [38]. Our results agree with the findings in the literature. It has been documented that presence of ulceration has no significant association with LNM [39]. On the other hand, a study suggested that ulceration was an independent factor for LNM in EGC. Ulcerations were present in all LMN cases in T1a cancer [40]. Moreover, we noted greater tumour sizes and higher numbers of LNMs in patients with ulceration. Along with an increase in the diameter of the tumour, the incidence of LNM in EGC rises, both in T1a and in T1b cancer. A larger tumour diameter (≥2 cm) independently predicted LNM in poorly differentiated-type EGC. Our finding does not differ from large series published by Eastern authors. We observed greater tumour sizes in the T1b group and in LNM patients. Tumour sizes were larger in N2 patients (4.7 ± 1.3 cm) than in N1 (3.3 ± 0.8 cm) and N0 patients (1.9 ± 0.5 cm). Moreover, we reported that the number of LNMs was higher in tumours > 3 cm (2.1 ± 1.0) than in smaller tumours (1.5 ± 0.5, p = 0.006).
Further risk factors include L or LESS location. In these areas, the submucosa is thinner, and the lymphatic vessels more widespread in the lamina propria of the mucosa [41]. It has been demonstrated that tumour location is a significant but not independent factor for LNM in undifferentiated EGC. Nam et al. studied 2524 patients with T1a cancer and found that the ratio of LNM in tumours located in the upper, middle, and lower third parts in patients were 1.4%, 2.3%, and 2.3%, respectively. However, there was not a significant difference [38]. We observed a greater number of LNMs in L tumours (2.1 ± 0.9) than in M tumours (1.4 ± 0.8, p = 0.001), with no differences between GRE (1.9 ± 1.0) and LESS locations (1.9 ± 0.9, p = 0.4). Our results are confirmed by other studies in the literature in which a marked increase in LN involvement in distal EGC has been observed [42].
In our patients, LMNs were detected only in perigastric stations. However, our study highlighted that tumours with N2 LNMs were submucosal with a diameter greater than 3.0 cm. Thus, we suggest that submucosal cancer with a diameter greater than 3.0 cm is a risk factor for LNM. It has been observed that LNM starts with deep mucosal infiltration and as the invasion depth increases, the rate of LNM rises [3,8,13,14,22,31,33]. Our results agree that depth of invasion is one of the most important risk factors for LNMs. In the present study, T1b cancer was associated with a higher number of LNMs than in mucosal invasion, despite the fact that no LNM from station 7 to 12 was observed in our patients. D1+ lymphadenectomy has been recommended in Eastern countries for EGC where alternative treatment is considered unlikely to be effective [5,25,34].
However, the optimal extent of extragastric LN stations that should be included in D1+ lymphadenectomy has not been established. For this reason, D2 lymphadenectomy is considered the standard treatment for EGC. The guidelines recommend removing a minimum of 16 LNs. The removal of at least 16 LNs would allow the N stage to be precisely defined. A lymphadenectomy of at least 16 LNs would not lead to an increase in postoperative mortality [6,13,25,30,34,42]. The number of retrieved LNs serves as prognostic factor for gastric cancer, despite the fact that the optimal number of retrieved LNs remains controversial. Usually, the number of LNs is related to the extent of surgical intervention, which is also related to the depth of tumour invasion. As the depth increases, the number of LNs also increases. In our study, all cases of EGC had a radical gastrectomy and the difference between the number of retrieved LNs in T1a and in T1b cancer was not significantly different (p = 0.3).
This study has some limitations. First, the sample size was small. Second, this study’s retrospective nature can lead to potential bias. Third, we excluded patients with adenocarcinoma of the upper third of the stomach (Siewert III cancer) from the evaluation. Although it is commonly accepted that these tumours should be treated in the same way as mid-distal gastric cancer, patients with tumours of the upper third of the stomach were not included in the present study because the lymphatic flow in these cases is directed towards LN groups which are not included in D2 lymphadenectomy. Moreover, the depth of submucosal invasion was not specified in the present study. We demonstrate that several factors are related to LNMs in EGC. The frequency of LNM increases with the depth of invasion and a formal lymphadenectomy is necessary for the treatment of EGC. However, considering the limited research regarding a more tailored approach in the treatment of distal EGC, this study provides promising results. This preliminary work will need to be followed by further research concerning the extent of lymphadenectomy, with prospective and multicentre studies.

5. Conclusions

Our study revealed a relatively high incidence of LNM in EGC compared with Japanese and Korean cohorts. Large tumour size, undifferentiated type, ulceration, diffuse histological form, lower third location, and submucosal invasion were recognised as risk factors for LMN in EGC. In these patients, a radical gastrectomy with lymphadenectomy should be performed.

Author Contributions

M.M.C.: Conceptualisation, Methodology, Writing—Reviewing and Editing. S.V.: Investigation, Formal analysis, Data curation. P.F.: Data curation, Investigation, Formal analysis. V.B.: Investigation, Formal analysis, Writing—Reviewing and Editing. V.F.: Investigation, Formal analysis, Data curation. A.C.: Data curation, Formal analysis. G.T.: Data curation, Formal analysis. G.B.: Conceptualisation, Methodology, Data curation, Formal analysis, Writing—Original draft, Writing—Reviewing and Editing. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. This article does not contain any experimental studies with human participants performed by any of the authors. Ethical review and approval were waived for this study due to it being a retrospective analysis of deidentified data.

Informed Consent Statement

Informed consent was obtained from all subjects involved in this study.

Data Availability Statement

The authors confirm that the data supporting the findings of this study are available within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Bergquist, J.R.; Leiting, J.L.; Habermann, E.B.; Cleary, S.P.; Kendrick, M.L.; Smoot, R.L.; Nagorney, D.M.; Truty, M.J.; Grotz, T.E. Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. Surgery 2019, 166, 547–555. [Google Scholar] [CrossRef] [PubMed]
  2. Zhao, L.; Han, W.; Niu, P.; Lu, Y.; Zhang, F.; Jiao, F.; Zhou, X.; Wang, W.; Luan, X.; He, M.; et al. Using nomogram, decision tree, and deep learning models to predict lymph node metastasis in patients with early gastric cancer: A multi-cohort study. Am. J. Cancer Res. 2023, 13, 204–215. [Google Scholar] [PubMed]
  3. Chiarello, M.M.; Fico, V.; Pepe, G.; Tropeano, G.; Adams, N.J.; Altieri, G.; Brisinda, G. Early gastric cancer: A challenge in Western countries. World J. Gastroenterol. 2022, 28, 693–703. [Google Scholar] [CrossRef] [PubMed]
  4. Chen, X.-D.; Chen, Q.-C.; Xu, R.; Zhao, F.-Z. Therapeutic value of lymph node dissection for Siewert type II and III adenocarcinoma: Meta-analysis. BJS Open 2024, 8, zrad138. [Google Scholar] [CrossRef]
  5. Akiyama, Y.; Katai, H.; Kitabayashi, R.; Nunobe, S.; Koeda, K.; Yura, M.; Sato, Y.; Yoshikawa, T.; Terashima, M. Frequency of lymph node metastasis according to tumor location in clinical T1 early gastric cancer: Supplementary analysis of the Japan Clinical Oncology Group study (JCOG0912). J. Gastroenterol. 2023, 58, 519–526. [Google Scholar] [CrossRef] [PubMed]
  6. Brisinda, G.; Chiarello, M.M.; Fico, V.; Puccioni, C.; Crocco, A.; Bianchi, V.; Vanella, S. Pattern of Distribution of Lymph Node Metastases in Individual Stations in Middle and Lower Gastric Carcinoma. Cancers 2023, 15, 2139. [Google Scholar] [CrossRef] [PubMed]
  7. Oh, Y.J.; Kim, D.H.; Han, W.H.; Eom, B.W.; Kim, Y.I.; Yoon, H.M.; Lee, J.Y.; Kim, C.G.; Kook, M.C.; Choi, I.J.; et al. Risk factors for lymph node metastasis in early gastric cancer without lymphatic invasion after endoscopic submucosal dissection. Eur. J. Surg. Oncol. 2021, 47, 3059–3063. [Google Scholar] [CrossRef]
  8. Chen, J.; Zhao, G.; Wang, Y. Analysis of lymph node metastasis in early gastric cancer: A single institutional experience from China. World J. Surg. Oncol. 2020, 18, 57. [Google Scholar] [CrossRef] [PubMed]
  9. Cai, F.; Dong, Y.; Wang, P.; Zhang, L.; Yang, Y.; Liu, Y.; Wang, X.; Zhang, R.; Liang, H.; Sun, Y.; et al. Risk assessment of lymph node metastasis in early gastric cancer: Establishment and validation of a Seven-point scoring model. Surgery 2022, 171, 1273–1280. [Google Scholar] [CrossRef]
  10. Kamarajah, S.K.; Markar, S.R.; Phillips, A.W.; Salti, G.I.; Dahdaleh, F.S. Local Endoscopic Resection is Inferior to Gastrectomy for Early Clinical Stage T1a and T1b Gastric Adenocarcinoma: A Propensity-Matched Study. Ann. Surg. Oncol. 2021, 28, 2992–2998. [Google Scholar] [CrossRef]
  11. Newland, J.J.; Johnson, A.M.; Feng, Z.; Kim, R.E.; Williams, R.T.; Hanna, N.N.; Mullins, C.D.; Hu, Y. Increasing utilization of endoscopic local excision for early-stage gastric cancers in the United States. Surgery 2022, 172, 169–176. [Google Scholar] [CrossRef] [PubMed]
  12. Tong, J.H.; Sun, Z.; Wang, Z.N.; Zhao, Y.H.; Huang, B.J.; Li, K.; Xu, Y.; Xu, H.M. Early gastric cancer with signet-ring cell histologic type: Risk factors of lymph node metastasis and indications of endoscopic surgery. Surgery 2011, 149, 356–363. [Google Scholar] [CrossRef] [PubMed]
  13. Watanabe, A.; McKendry, G.J.; Yip, L.; Donnellan, F.; Hamilton, T.D. Risk of lymph node metastasis in early gastric cancer for a Western population. J. Surg. Oncol. 2023, 127, 791–797. [Google Scholar] [CrossRef] [PubMed]
  14. Zhu, H.; Wang, G.; Zheng, J.; Zhu, H.; Huang, J.; Luo, E.; Hu, X.; Wei, Y.; Wang, C.; Xu, A.; et al. Preoperative prediction for lymph node metastasis in early gastric cancer by interpretable machine learning models: A multicenter study. Surgery 2022, 171, 1543–1551. [Google Scholar] [CrossRef]
  15. Ren, M.H.; Qi, X.S.; Chu, Y.N.; Yu, Y.N.; Chen, Y.Q.; Zhang, P.; Mao, T.; Tian, Z.B. Risk of Lymph Node Metastasis and Feasibility of Endoscopic Treatment in Ulcerative Early Gastric Cancer. Ann. Surg. Oncol. 2021, 28, 2407–2417. [Google Scholar] [CrossRef]
  16. Milhomem, L.M.; Milhomem-Cardoso, D.M.; da Mota, O.M.; Mota, E.D.; Kagan, A.; Filho, J.B.S. Risk of lymph node metastasis in early gastric cancer and indications for endoscopic resection: Is it worth applying the east rules to the west? Surg. Endosc. 2021, 35, 4380–4388. [Google Scholar] [CrossRef] [PubMed]
  17. Li, C.; Xie, S.; Chen, D.; Zhang, J.; Zhang, N.; Mu, J.; Gong, A. Clinicopathological characteristics of early gastric cancer with different level of undifferentiated component and nomogram to predict lymph node metastasis. Front. Surg. 2023, 10, 1097927. [Google Scholar] [CrossRef] [PubMed]
  18. Sekiguchi, M.; Oda, I.; Taniguchi, H.; Suzuki, H.; Morita, S.; Fukagawa, T.; Sekine, S.; Kushima, R.; Katai, H. Risk stratification and predictive risk-scoring model for lymph node metastasis in early gastric cancer. J. Gastroenterol. 2016, 51, 961–970. [Google Scholar] [CrossRef]
  19. Paredes, O.; Baca, C.; Cruz, R.; Paredes, K.; Luque-Vasquez, C.; Chavez, I.; Taxa, L.; Ruiz, E.; Berrospi, F.; Payet, E. Predictive factors of lymphatic metastasis and evaluation of the Japanese treatment guidelines for endoscopic resection of early gastric cancer in a high-volume center in Peru. Heliyon 2023, 9, e16293. [Google Scholar] [CrossRef]
  20. Fan, X.; Shi, C.; Lu, D. High risk factors related to lymph node metastasis in early gastric cancer: A retrospective observational study. Medicine 2023, 102, e33431. [Google Scholar] [CrossRef]
  21. Yang, S.; Gu, X.; Tao, R.; Huo, J.; Hu, Z.; Sun, F.; Ni, J.; Wang, X. Relationship between histological mixed-type early gastric cancer and lymph node metastasis: A systematic review and meta-analysis. PLoS ONE 2022, 17, e0266952. [Google Scholar] [CrossRef] [PubMed]
  22. Vos, E.L.; Nakauchi, M.; Gonen, M.; Castellanos, J.A.; Biondi, A.; Coit, D.G.; Dikken, J.L.; D’Ugo, D.; Hartgrink, H.; Li, P.; et al. Risk of Lymph Node Metastasis in T1b Gastric Cancer: An International Comprehensive Analysis from the Global Gastric Group (G3) Alliance. Ann. Surg. 2023, 277, e339–e345. [Google Scholar] [CrossRef] [PubMed]
  23. Kim, E.R.; Lee, H.; Min, B.H.; Lee, J.H.; Rhee, P.L.; Kim, J.J.; Kim, K.M.; Kim, S. Effect of rescue surgery after non-curative endoscopic resection of early gastric cancer. Br. J. Surg. 2015, 102, 1394–1401. [Google Scholar] [CrossRef]
  24. Abe, N.; Watanabe, T.; Suzuki, K.; Machida, H.; Toda, H.; Nakaya, Y.; Masaki, T.; Mori, T.; Sugiyama, M.; Atomi, Y. Risk factors predictive of lymph node metastasis in depressed early gastric cancer. Am. J. Surg. 2002, 183, 168–172. [Google Scholar] [CrossRef] [PubMed]
  25. Lee, H.H.; Yoo, H.M.; Song, K.Y.; Jeon, H.M.; Park, C.H. Risk of limited lymph node dissection in patients with clinically early gastric cancer: Indications of extended lymph node dissection for early gastric cancer. Ann. Surg. Oncol. 2013, 20, 3534–3540. [Google Scholar] [CrossRef] [PubMed]
  26. von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gotzsche, P.C.; Vandenbroucke, J.P.; Initiative, S. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 2007, 370, 1453–1457. [Google Scholar] [CrossRef]
  27. Amin, M.B.; Greene, F.L.; Edge, S.B.; Compton, C.C.; Gershenwald, J.E.; Brookland, R.K.; Meyer, L.; Gress, D.M.; Byrd, D.R.; Winchester, D.P. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J. Clin. 2017, 67, 93–99. [Google Scholar] [CrossRef]
  28. Lauren, P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol. Microbiol. Scand. 1965, 64, 31–49. [Google Scholar] [CrossRef]
  29. Japanese Gastric Cancer, A. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011, 14, 113–123. [Google Scholar] [CrossRef]
  30. Brisinda, G.; Chiarello, M.M.; Crocco, A.; Adams, N.J.; Fransvea, P.; Vanella, S. Postoperative mortality and morbidity after D2 lymphadenectomy for gastric cancer: A retrospective cohort study. World J. Gastroenterol. 2022, 28, 381–398. [Google Scholar] [CrossRef]
  31. Holscher, A.H.; Drebber, U.; Monig, S.P.; Schulte, C.; Vallbohmer, D.; Bollschweiler, E. Early gastric cancer: Lymph node metastasis starts with deep mucosal infiltration. Ann. Surg. 2009, 250, 791–797. [Google Scholar] [CrossRef] [PubMed]
  32. Li, G.Z.; Doherty, G.M.; Wang, J. Surgical Management of Gastric Cancer: A Review. JAMA Surg. 2022, 157, 446–454. [Google Scholar] [CrossRef] [PubMed]
  33. Pereira, C.; Park, J.H.; Campelos, S.; Gullo, I.; Lemos, C.; Solorzano, L.; Martins, D.; Goncalves, G.; Leitao, D.; Lee, H.J.; et al. Comparison of East-Asia and West-Europe cohorts explains disparities in survival outcomes and highlights predictive biomarkers of early gastric cancer aggressiveness. Int. J. Cancer 2022, 150, 868–880. [Google Scholar] [CrossRef] [PubMed]
  34. Yoo, H.J.; Lee, H.; Lee, H.H.; Lee, J.H.; Jun, K.H.; Kim, J.J.; Song, K.Y.; Kim, D.J. A Nomogram for Predicting Extraperigastric Lymph Node Metastasis in Patients With Early Gastric Cancer. J. Gastric Cancer 2023, 23, 355–364. [Google Scholar] [CrossRef] [PubMed]
  35. Gunji, Y.; Suzuki, T.; Hori, S.; Hayashi, H.; Matsubara, H.; Shimada, H.; Ochiai, T. Prognostic significance of the number of metastatic lymph nodes in early gastric cancer. Dig. Surg. 2003, 20, 148–153. [Google Scholar] [CrossRef]
  36. Jeon, C.H.; Park, K.B.; Kim, S.; Seo, H.S.; Kim, I.H.; Song, K.Y.; Lee, H.H. Determination of the extent of dissection in early gastric cancer based on lymph node station power index. BJS Open 2022, 6, zrac104. [Google Scholar] [CrossRef]
  37. Wang, Z.K.; Lin, J.X.; Li, P.; Xie, J.W.; Wang, J.B.; Lu, J.; Chen, Q.Y.; Cao, L.L.; Lin, M.; Tu, R.H.; et al. Higher Risk of Lymph Node Metastasis in Young Patients with Early Gastric Cancer. J. Cancer 2019, 10, 4389–4396. [Google Scholar] [CrossRef] [PubMed]
  38. Nam, M.J.; Oh, S.J.; Oh, C.A.; Kim, D.H.; Bae, Y.S.; Choi, M.G.; Noh, J.H.; Sohn, T.S.; Bae, J.M.; Kim, S. Frequency and predictive factors of lymph node metastasis in mucosal cancer. J. Gastric Cancer 2010, 10, 162–167. [Google Scholar] [CrossRef]
  39. Park, J.W.; Ahn, S.; Lee, H.; Min, B.H.; Lee, J.H.; Rhee, P.L.; Kim, K.M.; Kim, J.J. Predictive factors for lymph node metastasis in early gastric cancer with lymphatic invasion after endoscopic resection. Surg. Endosc. 2017, 31, 4419–4424. [Google Scholar] [CrossRef]
  40. Haruta, H.; Hosoya, Y.; Sakuma, K.; Shibusawa, H.; Satoh, K.; Yamamoto, H.; Tanaka, A.; Niki, T.; Sugano, K.; Yasuda, Y. Clinicopathological study of lymph-node metastasis in 1,389 patients with early gastric cancer: Assessment of indications for endoscopic resection. J. Dig. Dis. 2008, 9, 213–218. [Google Scholar] [CrossRef]
  41. Listrom, M.B.; Fenoglio-Preiser, C.M. Gastric lymphatics. Am. J. Surg. Pathol. 1987, 11, 156. [Google Scholar] [CrossRef] [PubMed]
  42. Ren, G.; Cai, R.; Zhang, W.J.; Ou, J.M.; Jin, Y.N.; Li, W.H. Prediction of risk factors for lymph node metastasis in early gastric cancer. World J. Gastroenterol. 2013, 19, 3096–3107. [Google Scholar] [CrossRef] [PubMed]
Table 1. Demographic and clinicopathological characteristics in all patients.
Table 1. Demographic and clinicopathological characteristics in all patients.
Variables * N. of Patients%
Age≤65 years8162.7
>65 years4837.3
SexMale7155.0
Female5845.0
Tumour size≤3.0 cm7558.1
>3.0 cm5441.9
Macroscopic appearanceDepressed4232.5
Elevated8767.5
UlcerationAbsent9069.7
Present3930.3
Lauren criteriaDiffuse5542.6
Intestinal7457.4
DifferentiationDifferentiated7658.9
Undifferentiated5341.1
Circular locationM4031.0
L8969.0
Longitudinal locationGRE5441.9
LESS7558.1
DepthT1a7961.2
T1b5038.8
SurgerySubtotal gastrectomy9472.8
Total gastrectomy3527.2
N statusN-5341.0
LNM7659.0
N stageN05341.0
N16248.0
N21411.0
* GRE: greater curvature; L: lower third; LESS: lesser curvature; LNM: lymph node metastasis; M: middle third.
Table 2. Tumour size in relation to the clinical, anatomical, and pathological parameters considered in all patients.
Table 2. Tumour size in relation to the clinical, anatomical, and pathological parameters considered in all patients.
Variables * Size (cm)p Value
Age≤65 years3.1 ± 1.20.02
>65 years2.6 ± 1.1
SexMale3.1 ± 1.20.02
Female2.7 ± 1.2
Macroscopic appearanceDepressed3.6 ± 1.30.00001
Elevated2.6 ± 0.9
UlcerationAbsent2.6 ± 1.00.00001
Present3.6 ± 1.4
Lauren criteriaDiffuse3.4 ± 1.10.00001
Intestinal2.5 ± 1.1
DifferentiationDifferentiated2.5 ± 0.90.00001
Undifferentiated3.6 ± 1.3
Circular locationM2.7 ± 1.00.1
L3.0 ± 1.3
Longitudinal locationGRE3.1 ± 1.30.04
LESS2.8 ± 1.1
DepthT1a2.5 ± 0.90.00001
T1b3.5 ± 1.3
SurgerySubtotal gastrectomy2.9 ± 1.20.3
Total gastrectomy2.8 ± 1.0
N statusN-1.9 ± 0.50.00001
LNM3.6 ± 1.0
N stageN01.9 ± 0.50.00001
N13.3 ± 0.8
N24.7 ± 1.3
* GRE: greater curvature; L: lower third; LESS: lesser curvature; LNM: lymph node metastasis; M: middle third.
Table 3. Number of LNMs in relation to the clinicopathological parameters considered in node-positive patients.
Table 3. Number of LNMs in relation to the clinicopathological parameters considered in node-positive patients.
Variables * N. of LNMsp Value
Age≤65 years1.8 ± 0.90.09
>65 years2.1 ± 1.0
SexMale1.7 ± 0.80.04
Female2.1 ± 1.0
Tumour size≤3.0 cm1.5 ± 0.50.006
>3.0 cm2.1 ± 1.0
Macroscopic appearanceDepressed2.6 ± 0.90.00001
Elevated1.3 ± 0.4
UlcerationAbsent1.3 ± 0.50.00001
Present2.6 ± 0.9
Lauren criteriaDiffuse2.1 ± 0.90.002
Intestinal1.5 ± 0.9
DifferentiationDifferentiated1.3 ± 0.50.00001
Undifferentiated2.3 ± 0.9
Circular locationM1.4 ± 0.80.001
L2.1 ± 0.9
Longitudinal locationGRE1.9 ±1.00.4
LESS1.9 ± 0.9
DepthT1a1.3 ± 0.50.00001
T1b2.4 ± 1.0
SurgerySubtotal gastrectomy2.1 ± 0.90.008
Total gastrectomy1.5 ± 0.8
* GRE: greater curvature; L: lower third; LESS: lesser curvature; LNM: lymph node metastasis; M: middle third.
Table 4. Demographic and clinicopathological characteristics of T1a gastric cancer compared with T1b gastric cancer.
Table 4. Demographic and clinicopathological characteristics of T1a gastric cancer compared with T1b gastric cancer.
Variables * T1aT1bp Value
Age≤65 years45360.09
>65 years3414
SexMale45260.5
Female3424
Tumour size≤3.0 cm57180.0001
>3.0 cm2232
Macroscopic appearanceDepressed13290.0001
Elevated6621
UlcerationAbsent67230.0001
Present1227
Lauren criteriaDiffuse58160.0001
Intestinal2134
DifferentiationDifferentiated58180.0001
Undifferentiated2132
Circular locationM27130.4
L5237
Longitudinal locationGRE32220.7
LESS4728
N statusN-4490.0001
LNM3541
* GRE: greater curvature; L: lower third; LESS: lesser curvature; LNM: lymph node metastasis; M: middle third.
Table 5. Risk factors for LNMs in T1a and T1b gastric cancer.
Table 5. Risk factors for LNMs in T1a and T1b gastric cancer.
Variables * T1aT1b
LN-LNMp ValueLN-LNMp Value
Age≤65 years23220.34320.09
>65 years2113 59
SexMale19260.0067190.1
Female259 222
Tumour size≤3.0 cm42150.00017110.006
>3.0 cm220 230
Macroscopic appearanceDepressed490.042270.02
Elevated4026 714
UlcerationAbsent41260.027160.03
Present39 225
Lauren criteriaDiffuse7140.021330.0002
Intestinal3721 88
DifferentiationDifferentiated37210.02990.0001
Undifferentiated714 032
Circular locationM15121.0670.005
L2923 334
Longitudinal locationGRE18141.02200.2
LESS2621 721
* GRE: greater curvature; L: lower third; LESS: lesser curvature; LN: lymph node; LNM: lymph node metastasis; M: middle third.
Table 6. Univariate analysis of risk factors for LNMs in EGC.
Table 6. Univariate analysis of risk factors for LNMs in EGC.
Variables * LN-LNMp Value
Age≤65 years27540.02
>65 years2622
SexMale26450.2
Female2731
Tumour size≤3.0 cm49260.0001
>3.0 cm450
Macroscopic appearanceDepressed6360.0001
Elevated4740
UlcerationAbsent48420.0001
Present534
Lauren criteriaDiffuse8470.0001
Intestinal4529
DifferentiationDifferentiated46300.0001
Undifferentiated746
Circular locationM21190.08
L3257
Longitudinal locationGRE20340.4
LESS3342
DepthT1a44350.0001
T1b941
* GRE: greater curvature; L: lower third; LESS: lesser curvature; LN: lymph node; LNM: lymph node metastasis; M: middle third.
Table 7. Univariate analysis of risk factors for LNMs in EGC in relation to depth of invasion.
Table 7. Univariate analysis of risk factors for LNMs in EGC in relation to depth of invasion.
Variables * LN-LNM
T1aT1bp ValueT1aT1bp Value
Age≤65 years2340.722320.2
>65 years215 139
SexMale1970.0726190.01
Female252 922
Tumour size≤3.0 cm4270.115110.1
>3.0 cm22 2030
Macroscopic appearanceDepressed420.29270.0006
Elevated407 2614
UlcerationAbsent4170.126160.002
Present32 925
Lauren criteriaDiffuse711.014330.0004
Intestinal378 218
DifferentiationDifferentiated3790.32190.001
Undifferentiated70 1432
Circular locationM1560.11270.1
L293 2334
Longitudinal locationGRE1820.414200.4
LESS267 2121
* GRE: greater curvature; L: lower third; LESS: lesser curvature; LN: lymph node; LNM: lymph node metastasis; M: middle third.
Table 8. Multivariate analysis of risk factors for LNMs in EGC.
Table 8. Multivariate analysis of risk factors for LNMs in EGC.
Variables * ORWald95% CIp Value
Tumour size≤3.0 cm14.00519.4551.467 3.8120.001
>3.0 cm
UlcerationAbsent1.0470.289−1.064 1.8680.003
Present
Lauren criteriaDiffuse0.1514.684−3.604 −0.1780.03
Intestinal
DifferentiationDifferentiated13.4396.5640.611 4.5860.01
Undifferentiated
Circular locationM0.0624.995−5.207 −0.3410.02
L
DepthT1a15.0346.9570.696 4.7240.008
T1b
* L: lower third; M: middle third; OR: odds ratio; CI: confidence interval.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Chiarello, M.M.; Vanella, S.; Fransvea, P.; Bianchi, V.; Fico, V.; Crocco, A.; Tropeano, G.; Brisinda, G. Risk Factors for Lymph Node Metastasis in a Western Series of Patients with Distal Early Gastric Cancer. J. Clin. Med. 2024, 13, 2659. https://doi.org/10.3390/jcm13092659

AMA Style

Chiarello MM, Vanella S, Fransvea P, Bianchi V, Fico V, Crocco A, Tropeano G, Brisinda G. Risk Factors for Lymph Node Metastasis in a Western Series of Patients with Distal Early Gastric Cancer. Journal of Clinical Medicine. 2024; 13(9):2659. https://doi.org/10.3390/jcm13092659

Chicago/Turabian Style

Chiarello, Maria Michela, Serafino Vanella, Pietro Fransvea, Valentina Bianchi, Valeria Fico, Anna Crocco, Giuseppe Tropeano, and Giuseppe Brisinda. 2024. "Risk Factors for Lymph Node Metastasis in a Western Series of Patients with Distal Early Gastric Cancer" Journal of Clinical Medicine 13, no. 9: 2659. https://doi.org/10.3390/jcm13092659

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop